Matinas BioPharma Holdings MTNB
NYSE MTNB
$2.55 -0.33 (-11.46%)
As of: Sep 30, 2026 · 3:59 PM EDT

Matinas BioPharma Holdings (MTNB) Current Deferred Revenue (2017)

Updated

Matinas BioPharma Holdings' Current Deferred Revenue came in at $29,937 for Q4 2017, down 60.0% from the prior quarter.

Analysis

Matinas BioPharma Holdings (MTNB) Current Deferred Revenue (2017) Analysis & Trends

Going back to Q1 2017, Matinas BioPharma Holdings' Current Deferred Revenue data covers 4 quarters.

  • Business Quant data shows MTNB's Current Deferred Revenue at $74,844 (Q3 2017), $119,750 (Q2 2017) and $164,656 (Q1 2017) in the three quarters before Q4 2017.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 Matinas BioPharma Holdings 18.13 Mn 5.54 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2017 29,937.00
Sep 30, 2017 74,844.00
Jun 30, 2017 119,750.00
Mar 31, 2017 164,656.00
API Access

Matinas BioPharma Holdings Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=MTNB&period=max&api_key=YOUR_API_KEY